These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38400138)

  • 1. High-Throughput Screening for the Prevalence of Neutralizing Antibodies against Human Adenovirus Serotype 5.
    Wettengel JM; Naka H; Dissen GA; Torgerson J; Pounder M; Mueller SF; Mueller E; Hagen P; Brandt M; Protzer U; Burwitz BJ
    Vaccines (Basel); 2024 Feb; 12(2):. PubMed ID: 38400138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the Prevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Student Cohorts Reveals Low-Prevalence Types and a Decline in Binding Antibody Levels during the SARS-CoV-2 Pandemic.
    Wang X; Kerkmann L; Hetzel M; Windmann S; Trilling M; Zhang W; Ehrhardt A; Bayer W
    J Virol; 2022 Nov; 96(22):e0113322. PubMed ID: 36342295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy.
    Sayedahmed EE; Kumari R; Shukla S; Hassan AO; Mohammed SI; York IA; Gangappa S; Sambhara S; Mittal SK
    Vaccine; 2018 Oct; 36(45):6744-6751. PubMed ID: 30266488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of human adenovirus type 5 neutralizing antibodies in the Philippines.
    Francisco AG; Reyes JCB; Tabios IKB; Cruz CJG; Ang MAC; Heralde FM; Lacuna ARG; de Paz-Silava SLM
    PLoS One; 2023; 18(12):e0293046. PubMed ID: 38039314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of an adenoviral vaccine vector based on simian adenovirus 21.
    Roy S; Zhi Y; Kobinger GP; Figueredo J; Calcedo R; Miller JR; Feldmann H; Wilson JM
    J Gen Virol; 2006 Sep; 87(Pt 9):2477-2485. PubMed ID: 16894185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a Critical and Conformational Neutralizing Epitope in Human Adenovirus Type 4 Hexon.
    Tian X; Qiu H; Zhou Z; Wang S; Fan Y; Li X; Chu R; Li H; Zhou R; Wang H
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29093098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Patients with Neuromuscular Disorders.
    Klann PJ; Wang X; Elfert A; Zhang W; Köhler C; Güttsches AK; Jacobsen F; Weyen U; Roos A; Ehrke-Schulz E; Ehrhardt A; Vorgerd M; Bayer W
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of neutralizing monoclonal antibodies against a conformational epitope of human adenovirus type 7 (HAdv-7) incorporated in capsid encoded in a HAdv-3-based vector.
    Liu M; Tian X; Li X; Zhou Z; Li C; Zhou R
    PLoS One; 2014; 9(7):e103058. PubMed ID: 25054273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simian adenoviruses as vaccine vectors.
    Morris SJ; Sebastian S; Spencer AJ; Gilbert SC
    Future Virol; 2016 Sep; 11(9):649-659. PubMed ID: 29527232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates.
    Bots STF; Kemp V; Cramer SJ; van den Wollenberg DJM; Hornsveld M; Lamfers MLM; van der Pluijm G; Hoeben RC
    Hum Gene Ther; 2022 Mar; 33(5-6):275-289. PubMed ID: 34861769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus Type 6: Subtle Structural Distinctions from Adenovirus Type 5 Result in Essential Differences in Properties and Perspectives for Gene Therapy.
    Romanenko M; Osipov I; Netesov SV; Davydova J
    Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Fiber Knob Protein of Human Adenovirus Type 49 Mediates Highly Efficient and Promiscuous Infection of Cancer Cell Lines Using a Novel Cell Entry Mechanism.
    Baker AT; Davies JA; Bates EA; Moses E; Mundy RM; Marlow G; Cole DK; Bliss CM; Rizkallah PJ; Parker AL
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33268514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55.
    Liu T; Zhou Z; Tian X; Liu W; Xu D; Fan Y; Liao J; Gu S; Li X; Zhou R
    Vaccine; 2018 Apr; 36(16):2199-2206. PubMed ID: 29548605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human AdV-20-42-42, a Promising Novel Adenoviral Vector for Gene Therapy and Vaccine Product Development.
    Ballmann MZ; Raus S; Engelhart R; Kaján GL; Beqqali A; Hadoke PWF; van der Zalm C; Papp T; John L; Khan S; Boedhoe S; Danskog K; Frängsmyr L; Custers J; Bakker WAM; van der Schaar HM; Arnberg N; Lemckert AAC; Havenga M; Baker AH
    J Virol; 2021 Oct; 95(22):e0038721. PubMed ID: 34469243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and Characterization of a Novel Recombinant Attenuated and Replication-Deficient Candidate Human Adenovirus Type 3 Vaccine: "Adenovirus Vaccine Within an Adenovirus Vector".
    Yan Y; Jing S; Feng L; Zhang J; Zeng Z; Li M; Zhao S; Ou J; Lan W; Guan W; Wu X; Wu J; Seto D; Zhang Q
    Virol Sin; 2021 Jun; 36(3):354-364. PubMed ID: 32458297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions.
    Qiu H; Li X; Tian X; Zhou Z; Xing K; Li H; Tang N; Liu W; Bai P; Zhou R
    J Virol; 2012 Aug; 86(15):7964-75. PubMed ID: 22623776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of Neutralizing Antibodies against Six Human Adenovirus Types Indicates the Low Level of Herd Immunity in Young Children from Guangzhou, China.
    Tian X; Fan Y; Wang C; Liu Z; Liu W; Xu Y; Mo C; You A; Li X; Rong X; Zhou R
    Virol Sin; 2021 Jun; 36(3):373-381. PubMed ID: 33165772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes.
    Uchino J; Curiel DT; Ugai H
    PLoS One; 2014; 9(2):e87342. PubMed ID: 24503714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development.
    Luo S; Zhang P; Ma X; Wang Q; Lu J; Liu B; Zhao W; Allain JP; Li C; Li T
    Virus Res; 2019 Jul; 268():1-10. PubMed ID: 31108113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.
    Malherbe DC; Mendy J; Vang L; Barnette PT; Reed J; Lakhashe SK; Owuor J; Gach JS; Legasse AW; Axthelm MK; LaBranche CC; Montefiori D; Forthal DN; Park B; Wilson JM; McLinden JH; Xiang J; Stapleton JT; Sacha JB; Haynes BF; Liao HX; Ruprecht RM; Smith J; Gurwith M; Haigwood NL; Alexander J
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29093095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.